BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia (Q35022511)

5 August 2017

1 reference

title

BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia (English)

1 reference

5 August 2017

1 reference

2

1 reference

5 August 2017

Stephanie Salesse

1

1 reference

PubMed ID

12476301

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

21

1 reference

5 August 2017

56

1 reference

5 August 2017

8547-8559

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1206082

5 August 2017

0 references

cites work

Cellular immunologic studies of a patient with monocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Differential complementation of Bcr-Abl point mutants with c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Roots of clinical resistance to STI-571 cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Tyrosine protein kinase inhibition and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Evolution of bone marrow transplantation--the original immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Molecular mechanisms of action of antisense drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Activation of the cell death program by inhibition of proteasome function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Antisense oligonucleotides as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Farnesyltransferase inhibitors versus Ras inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Ribozymes. Their functions and strategies for their use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

All ras proteins are polyisoprenylated but only some are palmitoylated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

What makes an mRNA anti-sense-itive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

CML vaccines as a paradigm of the specific immunotherapy of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Ribozymes: a distinct class of metalloenzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The c-kit proto-oncogene in normal and malignant human hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

BCR/ABL induces multiple abnormalities of cytoskeletal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Apoptosis induction resulting from proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Structure-function relationships of hammerhead ribozymes: from understanding to applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Antileukemia effect of c-myc N3'-->P5' phosphoramidate antisense oligonucleotides in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Activation of Raf as a result of recruitment to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Maxizymes, novel allosterically controllable ribozymes, can be designed to cleave various substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Properties of cloned and expressed human RNase H1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Retroviral vector design for gene therapy of cancer: specific inhibition and tagging of BCR-ABLp190 cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Interleukin-2 and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Allosterically controlled single-chained maxizymes with extremely high and specific activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206082

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1206082

1 reference

5 August 2017

1 reference

PubMed ID

12476301